GlaxoSmithKline Stock Price

Hedge fund Citadel takes short position in GSK, FT reports

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times reported on Friday.

Hosted on MSN · 10h

Citadel takes $384.5 million short position in GSK - FT

Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British pharmaceutical company. The Financial Times reported this on Friday that Citadel's short position is valued at 305 million pounds ($384.

Business Insider · 14h

GSK shares shorted by leading U.S. hedge fund, The Times reports

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s

Emma Walmsley Sells 120,653 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...

9don MSN

CFRA cuts GlaxoSmithKline stock price target to $40, maintains hold

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Yahoo Finance9d

GSK plc GSK Stock Forecast & Price Target

The January ISM Manufacturing PMI index registered a reading of 49.1, up from 47.1 in December, with growth in new orders, production, and prices, while backlogs, employment and inventories ...

ndtvprofit19h

GSK Pharma Q3 Results: Profit Increases Fivefold, Beats Estimates

Glaxosmithkline Pharmaceuticals reported a profit of Rs 230 crore in third quarter, a 400% year-on-year jump from Rs 46 crore ...

Growing optimism and a £2bn investor payout is a shot in the arm for this British giant

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

22h

GSK plc (NYSE:GSK) Shares Sold by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC lowered its holdings in GSK plc (NYSE:GSK – Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results